Colgate (CL) To Expand Skin Care Range With Filorga Buyout
Zacks Investment Research | Jul 12, 2019 07:33AM ET
After reaching the pinnacle in oral-care business, Colgate-Palmolive’s (NYSE:CL) quest for expanding in the high-margin personal care business brings another premium skin care range into its portfolio. The company agreed to buy the skin care business of France-based Laboratoires Filorga Cosmétiques (Filorga). The deal has been finalized for €1,495.5 million (US$1,690 million).
Sold in more than 60 countries, Filorga’s products mainly focus on facial care. This anti-aging skin care brand has its largest markets in France, Italy, Spain and Greater China. The brand is sold through a multi-channel distribution strategy, with supplies across pharmacy, online, specialty stores and travel retail.
With this acquisition, Colgate will take aboard a leading premium skin care brand, which will bring it high-growth, profitable, global skin care asset. The company is likely to benefit from the Filorga brand’s strong market positioning, with the scope to expand further through improved distribution and marketing. Moreover, this acquisition will mark Colgate’s entry into the fast-growing travel retail channel, particularly in Asia.
As part of its efforts to expand its personal care portfolio, the company acquired two professional skin care brands like PCA Skin and EltaMD in 2017. PCA Skin provides medical-grade in-office and take-home skin care products. The brand is also supported by highly professional dermatologists, plastic surgeons and aestheticians. EltaMD is a leader in physician-dispensed sun care services. Going forward, Colgate is likely to increase investments in professional skin care businesses — Elta MD and PCA Skin — in spas and dermatologists.
Coming back to Filorga, Colgate expects to finance the deal through cash and debt. It expects to close the transaction in third-quarter 2019, following the satisfaction of customary conditions and receiving the required regulatory approvals. However, the company does not expect the acquisition to influence its earnings in 2019.
We note that Colgate expects to improve organic sales in 2019 through accelerated investments in brands, strong innovation, and expansion in new markets and channels. For this, the company is focused on increasing the availability of its products through enhanced distribution to newer markets and channels. It is aggressively expanding into faster-growth channels while also extending the geographic footprint of its brands.
Apart from investments in Elta MD and PCA Skin, the company plans to expand the portfolio by introducing pharmacy brands like Elmex and Meridol to newer markets in 2019. It is also expanding e-commerce offerings, with the launch of Hill’s to home, which significantly exceeded subscription targets in the first quarter. This platform will enable pet parents to purchase prescription diet products directly from their veterinarian, with home delivery option. This should enable it to deliver strong e-commerce growth in 2019. All these actions are likely to drive solid top-line growth in 2019.
Get The News You Want
Backed by its continued efforts, this Zacks Rank #3 (Hold) stock has gained nearly 24.2% year to date compared with the industry ’s growth of 19.7%.
However, the company is plagued with soft margins and currency headwinds for a while now. Increased raw material and packaging costs as well as higher SG&A expenses are likely to hurt margins throughout 2019. Further, adverse currency should mar earnings and sales in 2019.
Three Better-Ranked Stocks in the Consumer Staples Sector
The Procter & Gamble Company (NYSE:PG) has a long-term earnings growth rate of 6.9% and a Zacks Rank #2 (Buy) at present. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.